|Bid||29.00 x 1400|
|Ask||33.80 x 800|
|Day's Range||30.66 - 31.24|
|52 Week Range||27.27 - 50.44|
|Beta (3Y Monthly)||1.56|
|PE Ratio (TTM)||44.00|
|Earnings Date||Feb 4, 2019 - Feb 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.67|
Is Myriad Genetics, Inc. (NASDAQ:MYGN) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict® at the San Antonio Breast Cancer Symposium in San Antonio, Texas. One of the key findings is that EndoPredict high-risk patients had a better outcome with adjuvant chemotherapy compared to endocrine therapy alone.
SALT LAKE CITY, Dec. 07, 2018 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that new data on its EndoPredict® test will be.
SALT LAKE CITY, Dec. 06, 2018 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from an important.
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Myriad Genetics Inc. said Monday it has entered an accelerated share buyback with Bank of America N.A. The company currently has about $161 million remaining on its share buyback authorization. Myriad specializes in molecular diagnostics aimed at determining the risk of developing disease. Shares were not yet active premarket, but have fallen 8.6% in 2018, while the S&P 500 has gained 2.3%.
Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced that the company has entered into an accelerated share repurchase (“ASR”) agreement with Bank of America, N.A. under which the company will repurchase approximately $50 million of its common stock. Myriad currently has approximately $161 million remaining on its existing share repurchase authorization which has been approved by the company’s board of directors. Under the ASR program, Myriad will pay an aggregate of approximately $50 million to Bank of America, N.A. to repurchase a number of shares that will be based on a discount to the volume-weighted average share price of its common stock over the course of a valuation period.
Three short years ago, Myriad Genetics was the undisputed leader of the genetic testing industry. A persistent competitor just challenged the diagnostic company -- and a second one is nipping at its heels.
With the markets currently facing a lot of gyration, investing in quality stocks seems prudent. After all, these stocks provide excellent risk-adjusted returns.
Cara Therapeutics (CARA) is a clinical-stage biotechnology company developing new chemical entities for managing pain and pruritus. Cara Therapeutics reported EPS of -$0.52 on revenue of $2.87 million in the second quarter.
Mark Capone has been the CEO of Myriad Genetics Inc (NASDAQ:MYGN) since 2015. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of Read More...
Myriad (MYGN) delivered earnings and revenue surprises of 43.33% and -0.80%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Salt Lake City-based company said it had a loss of 1 cent. Earnings, adjusted for non-recurring costs and stock option expense, were 43 cents per share. The results surpassed ...